PierianDx
Clinical genomics interpretation, now part of Velsera
Jan
2016
Company Event
Series A
Oct
2019
Company Event
$27M Series B
Jun
2021
Frazier Event
Frazier VC primary and secondary purchases
Nov
2021
Company Event
$30M growth capital
Jan
2023
Company Event
Acquired by Velsera
Capital Events Timeline
Company Overview
PierianDx provides software, services, and a curated clinical genomics knowledge base for labs to interpret genomic data and produce clinically actionable reports.
Why We Invested
PierianDx supports interpretation and reporting at the point where genomic data becomes clinical decision support, with defensibility through curated knowledge and integration depth.
Investment Vehicle
Frazier VC Fund III
Investor
Frazier VC
Founded
2014
Sector
Healthcare & Life Sciences
Legal Name
PierianDx, Inc. (now Velsera)
Status
Active
Other Investors
ATW Partners, SJF Ventures, Health Catalyst Capital, Inova Health System, RTI International, ARUP Laboratories, OrbiMed